These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 26419768)

  • 1. Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.
    Botzenhardt S; Sing CW; Wong IC; Chan GC; Wong LY; Felisi M; Rascher W; Ceci A; Neubert A
    Curr Drug Saf; 2016; 11(2):137-44. PubMed ID: 26419768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multi-center safety trial of the oral iron chelator deferiprone.
    Cohen A; Galanello R; Piga A; Vullo C; Tricta F
    Ann N Y Acad Sci; 1998 Jun; 850():223-6. PubMed ID: 9668543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety profile of the oral iron chelator deferiprone: a multicentre study.
    Cohen AR; Galanello R; Piga A; Dipalma A; Vullo C; Tricta F
    Br J Haematol; 2000 Feb; 108(2):305-12. PubMed ID: 10691860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases.
    Barman Balfour JA; Foster RH
    Drugs; 1999 Sep; 58(3):553-78. PubMed ID: 10493280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of oral iron chelator deferiprone in young thalassaemics.
    Naithani R; Chandra J; Sharma S
    Eur J Haematol; 2005 Mar; 74(3):217-20. PubMed ID: 15693791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.
    Maggio A; Kattamis A; Felisi M; Reggiardo G; El-Beshlawy A; Bejaoui M; Sherief L; Christou S; Cosmi C; Della Pasqua O; Del Vecchio GC; Filosa A; Cuccia L; Hassab H; Kreka M; Origa R; Putti MC; Spino M; Telfer P; Tempesta B; Vitrano A; Tsang YC; Zaka A; Tricta F; Bonifazi D; Ceci A
    Lancet Haematol; 2020 Jun; 7(6):e469-e478. PubMed ID: 32470438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis.
    Elalfy M; Wali YA; Qari M; Al Damanhouri G; Al-Tonbary Y; Yazman D; Al Hawsawi Z; Karakas Z; Kilinc Y; Yesilipek MA; Badr M; Elsafy U; Salama M; Abdel Rahman Y; Shebl S; Stilman A; Toiber Temin N; Tricta F
    Pediatr Blood Cancer; 2014 May; 61(5):879-84. PubMed ID: 24376176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferiprone-induced agranulocytosis: 20 years of clinical observations.
    Tricta F; Uetrecht J; Galanello R; Connelly J; Rozova A; Spino M; Palmblad J
    Am J Hematol; 2016 Oct; 91(10):1026-31. PubMed ID: 27415835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients.
    Ceci A; Baiardi P; Felisi M; Cappellini MD; Carnelli V; De Sanctis V; Galanello R; Maggio A; Masera G; Piga A; Schettini F; Stefàno I; Tricta F
    Br J Haematol; 2002 Jul; 118(1):330-6. PubMed ID: 12100170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deferiprone-associated myelotoxicity.
    al-Refaie FN; Wonke B; Hoffbrand AV
    Eur J Haematol; 1994 Nov; 53(5):298-301. PubMed ID: 7813710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experience with the oral iron chelator deferiprone in transfusion-dependent children.
    Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M; Karunatilaka DH; Weerasinghe I
    Ceylon Med J; 2002 Dec; 47(4):119-21. PubMed ID: 12661341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Orally active iron chelators in the treatment of iron overload.
    Olivieri NF
    Curr Opin Hematol; 1996 Mar; 3(2):125-30. PubMed ID: 9372062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The controversial role of deferiprone in the treatment of thalassemia.
    Richardson DR
    J Lab Clin Med; 2001 May; 137(5):324-9. PubMed ID: 11329529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continuation of deferiprone therapy in patients with mild neutropenia may not lead to a more severe drop in neutrophil count.
    El-Beshlawy AM; El-Alfy MS; Sari TT; Chan LL; Tricta F
    Eur J Haematol; 2014 Apr; 92(4):337-40. PubMed ID: 24330079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone.
    Cohen AR; Galanello R; Piga A; De Sanctis V; Tricta F
    Blood; 2003 Sep; 102(5):1583-7. PubMed ID: 12763939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Necrotizing stomatitis: a possible periodontal manifestation of deferiprone-induced agranulocytosis.
    Tewari S; Tewari S; Sharma RK; Abrol P; Sen R
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Oct; 108(4):e13-9. PubMed ID: 19778731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.
    Dadheech S; Rao AV; Shaheen U; Hussien MD; Jain S; Jyothy A; Munshi A
    Gene; 2013 Dec; 531(2):301-5. PubMed ID: 24036429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.